BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS

After Bristol-Myers Squibb closed its $74 billion Celgene deal this week, investors clamored for a contingent value right (CVR) that's now trading separately. But the CVR will only pay off if three highly anticipated drugs hit the market, making the security an exceptionally risky bet.